4th Annual MarketsandMarkets Biomarker and Companion Diagnostics Conference- London

Leveraging next gen technologies beyond conventional biomarker drug discovery

The emergence of the need for safety and efficacy of a drug subjected to individual patients has made companion diagnostics one of the most sought after topics in the field of In-Vitro Diagnostics. The surge of investment in companion diagnostics has brought forward issues regarding regulations and their intricacies and boosted new trends in immuno-oncology, immuno-therapies, data interpretation and unconventional design of clinical trials.

Key Highlights

• Clinical biomarker identification and qualification
• Biomarkers and personalized medicine
• Assay development and validation
• NGS and novel technologies in biomarker discovery
• Commercialization of biomarkers in therapeutic and CDx applications

Confirmed Speakers:

• Jenny Barnett , CEO, Monument Therapeutics
• Anita Grigoriadis , Reader in Cancer Bioinformatics, King’s College London
• Ian Pike , Chief Scientific Officer, Proteome Sciences PLC
• Andrew Pierce , Vice President, Translational Biology, Crescendo Biologics
• Huw Davies , VP, Global Sales, Owlstone Medical
• Nagy Habib , CMO, MiNA Therapeutics
• Batika Rana , Senior Scientist, Orchard Therapeutics